Related Experiment Video
Updated: May 17, 2026
10:10
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
[What's new concerning the chemobrain?]
1Service de neurologie, hôpital d'instruction des armées du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France. herve.taillia@santarm.fr
Revue Neurologique
|October 31, 2012
Summary
Chemobrain, a subtle cognitive decline after chemotherapy, is widely documented internationally but poorly recognized in France. This paper proposes a practical methodology to improve awareness and diagnosis of this chemotherapy side effect.
Area of Science:
- Neuroscience
- Oncology
- Cognitive Science
Context:
- Chemobrain, characterized by cognitive decline post-chemotherapy for non-cerebral cancers, is extensively reported internationally but remains underrecognized by French medical experts.
- Existing experimental evidence from animal models and functional neuroimaging is robust, yet clinical observations present contrasting findings, potentially due to methodological limitations.
Purpose:
- To address the underrecognition of chemobrain in France.
- To propose a practical methodology for identifying and managing chemobrain in daily clinical practice.
- To enhance awareness among oncologists and neurologists regarding chemotherapy-induced cognitive dysfunction.
Summary:
- This work reviews the current understanding of chemobrain, highlighting the discrepancy between international literature and French clinical practice.
- It discusses methodological challenges in diagnosing chemobrain in clinical settings.
- A proposed methodology, aligned with International Cognition and Cancer Task Force guidelines, is presented for practical application.
Impact:
- Increase awareness and recognition of chemobrain among French healthcare professionals.
- Facilitate earlier and more accurate diagnosis of chemotherapy-related cognitive impairment.
- Improve patient care by addressing a significant, yet often overlooked, side effect of cancer treatment.
More Related Videos
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:27Effects of Chemicals: Overview
Drugs, encompassing various chemical compounds from natural sources, lab synthesis, or genetic engineering, elicit different biological responses in living organisms. Some of these responses are desirable or therapeutic, while others are undesirable. The primary goal of administering a drug is to achieve a therapeutic effect, that is, to address a specific disease or health condition. Any concurrent effects outside of this therapeutic outcome are considered undesirable. These undesirable...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...